UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
September 28, 2004
Commission File Number 0-21392
AMARIN CORPORATION PLC
(Translation of registrant's name into English)
7 Curzon Street
London W1J 5HG
England
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
Form 20-F [X] Form 40-F [ ]
Indicate by check mark whether by furnishing the information contained
in this Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes [ ] No [X]
Attachment:
Material Events
(a) Amarin Corporation announces approval of resolutions at
Extraordinary General Meeting of Shareholders
This report on Form 6-K is hereby incorporated by reference
in (a) the registration statement on Form F-3 (Registration No.
333-104748) of Amarin Corporation plc and in the prospectus
contained therein, (b) the registration statement on Form F-3
(Registration No. 333-13200) of Amarin Corporation plc and in the
prospectus contained therein and (c) the registration statement on
Form F-3 (Regisstration No. 333-12642) of Amarin Corporation plc and
in the prospectus contained therein, and this report on Form 6-K
shall be deemed a part of each such registration statement from the
date on which this report is filed, to the extent not superseded by
documents or reports subsequently filed or furnished by Amarin
Corporation plc under the Securities Act of 1933 or the Securities
Exchange Act of 1934.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
AMARIN CORPORATION PLC
By: /s/ ALAN COOKE
Name: Alan Cooke
Title: Chief Financial Officer
Date: September 28, 2004
EXHIBIT INDEX
Index to Exhibits
Exhibit Item Sequentially Numbered Page
(a) Material event description 4
Contact:
Rick Stewart
Chief Executive Officer
Amarin Corporation plc
Phone: +44 (0) 207 907 2442
investor.relations@amarincorp.com
Alan Cooke
Chief Financial Officer
Amarin Corporation plc
Phone: +44 (0) 207 907 2442
AMARIN SHAREHOLDERS APPROVE ACQUISITION OF LAXDALE
LIMITED
- Amarin receives shareholder approval to purchase Laxdale Limited -
- Receives authorization to proceed with private offering of shares -
LONDON, United Kingdom, September 28, 2004 - Amarin Corporation plc
NASDAQSC: AMRN) today announced that the resolutions, as set out in
Amarin's Form 6-K dated September 1st 2004, to approve the acquisition
of Laxdale Limited and to authorize the equity financing, have been
passed at an Extraordinary General Meeting of its shareholders held
earlier today.
Rick Stewart, Chief Executive Officer of Amarin commented, "we are
pleased to have received overwhelming shareholder backing for the
Laxdale acquisition and the proposed equity financing and we would
hope to report shortly on our progress on these and other matters".
Amarin is a neuroscience company focused on the development and
commercialization of novel drugs for the treatment of neurological
disorders affecting the central nervous system. Amarin's leading
pipeline product, Miraxion, is in development for a number of
therapeutic indications including Huntington's disease ("HD") and
treatment-unresponsive depression. Amarin is listed on the Nasdaq
small cap market (ticker: AMRN), has headquarters in London and a
research and development facility in Stirling, Scotland.
Corporate Strategy
Amarin's goal is to capitalize on its strong reputation in neuroscience
and to become a leader in the development and commercialization of novel
drugs which address unmet medical needs. Amarin will develop its
late-stage development pipeline initially focusing on HD and depression.
Amarin will directly commercialize its neurology products in the U.S.
and out-license or partner its product rights in Europe and Japan. Amarin
will also out-license or partner its pipeline globally for indications
outside neurology.
Miraxion(TM) and Huntington's Disease
Miraxion(TM), Amarin's lead late-stage development product, is being
developed for the treatment of Huntington's disease, with phase III
trials due to commence in early 2005. Miraxion for Huntington's
disease has been granted Fast Track designation and received Orphan
Drug designation both in the U.S. and in Europe. Huntington's disease
is a genetic neurodegenerative disease characterized by movement disorder,
dementia and psychiatric disturbance. It has been diagnosed in
approximately 30,000 patients in the U.S. with a similar number in Europe.
Additionally, over 200,000 persons in the U.S. alone are genetically
"at risk" of developing the disease. Onset of symptoms is typically between
30-50 years of age with a typical life expectancy from diagnosis of 10-25
years. Patients with late stage disease require continuous nursing care,
often in nursing homes, with an estimated annual cost to the U.S. economy
of up to $2.5 billion. Presently, there is no effective treatment or cure
for Huntington's disease.
Miraxion and Treatment-Unresponsive Depression
Phase II clinical trials have been conducted with Miraxion in
treatment-unresponsive depression that concluded with statistical
significance that a 1-gram per day dose of Miraxion was effective
in treating depression in patients who remained depressed, despite
receiving standard therapy. The results of two trials were published
in the Archives of General Psychiatry in October 2002 and the
American Journal of Psychiatry in March 2002.
As a result of these encouraging clinical trial results, Amarin
intends to further evaluate the clinical benefits of Miraxion in
this indication and will seek a development and marketing partner
to accelerate the program.
About Amarin Corporation
Amarin Corporation plc is a neuroscience company focused on the development
and commercialisation of novel drugs for the treatment of central nervous
system disorders. Amarin's late-stage development product for Huntington's
disease is in phase III clinical trials.
For press releases and other corporate information, visit our website at
http://www.amarincorp.com.
Statements in this press release that are not historical facts are
forward-looking statements that involve risks and uncertainties which
may cause the Company's actual results in future periods to be materially
different from any performance suggested herein. Such risks and
uncertainties include, without limitation, the uncertainty of entering
into and consummating a definitive agreement on terms acceptable to the
parties, the inherent uncertainty of pharmaceutical research, product
development and commercialization, the impact of competitive products
and patents, as well as other risks and uncertainties detailed from time
to time in periodic reports. For more information, please refer to Amarin
Corporation's Annual Report for 2003 on Form 20-F and its Form 6-Ks as filed
with the U.S. Securities and Exchange Commission. The company assumes no
obligation to update information on its expectations.